#1 Clinical Trials Search in Europe

Floxuridine

Floxuridine, also known as FUDR, is being investigated in several clinical trials as a treatment for colorectal cancer that has spread to the liver. This article summarizes key information about ongoing research into floxuridine’s use in hepatic arterial infusion chemotherapy and other approaches for patients with colorectal liver metastases.

Table of Contents

What is Floxuridine?

Floxuridine, also known as FUDR, is a chemotherapy drug used in the treatment of various cancers[1]. It belongs to a class of medications called antimetabolites, which work by interfering with the growth of cancer cells[2]. Floxuridine is particularly effective in treating liver cancers because it has a very high first-pass extraction (about 95%) in the liver, meaning that most of the drug is absorbed and used by the liver before entering the general circulation[3].

What Conditions Does Floxuridine Treat?

Floxuridine is primarily used to treat the following conditions:

  • Colorectal Liver Metastases (CRLM): This refers to cancer that has spread from the colon or rectum to the liver[3][4].
  • Hepatocellular Carcinoma (HCC): A type of primary liver cancer[1].
  • Intrahepatic Cholangiocarcinoma (ICC): A cancer that forms in the bile ducts within the liver[1].
  • Gastric Cancer: Cancer that begins in the stomach[5].

How is Floxuridine Administered?

Floxuridine is typically administered through a method called Hepatic Arterial Infusion (HAI). This involves:

  1. Surgical Procedure: A catheter (thin tube) is placed directly into the hepatic artery, which supplies blood to the liver[3].
  2. Pump Placement: The catheter is connected to a small pump that is surgically implanted under the skin of the abdomen[4].
  3. Continuous Infusion: The pump delivers floxuridine directly to the liver over a period of time, usually 14 days[3].

This method allows for a high concentration of the drug to be delivered directly to the liver while minimizing exposure to the rest of the body, potentially reducing side effects[3].

Floxuridine in Combination Therapies

Floxuridine is often used in combination with other drugs to enhance its effectiveness. Some common combinations include:

  • Floxuridine + Dexamethasone: Dexamethasone is a steroid that helps reduce inflammation and may enhance the effects of floxuridine[1].
  • Floxuridine + Oxaliplatin: Oxaliplatin is another chemotherapy drug that can be used in combination with floxuridine to treat colorectal liver metastases[6].
  • Floxuridine + Irinotecan: Irinotecan is a chemotherapy drug that can be used systemically (throughout the body) while floxuridine is administered via HAI[6].
  • Floxuridine + Capecitabine + Oxaliplatin: This three-drug combination is being studied for its effectiveness in treating colorectal liver metastases[4].

Current Clinical Trials Using Floxuridine

Several clinical trials are ongoing to further investigate the effectiveness of floxuridine in various scenarios:

  • A study comparing HAI floxuridine plus systemic chemotherapy to systemic chemotherapy alone in patients with colorectal liver metastases[3].
  • A trial examining the use of floxuridine in combination with oxaliplatin and irinotecan for patients with initially unresectable colorectal liver metastases[6].
  • Research on using floxuridine as part of adjuvant therapy (treatment given after surgery) for patients who have had liver metastases removed[4].

Potential Side Effects

While HAI administration of floxuridine can help minimize systemic side effects, patients may still experience some adverse reactions. These can include:

  • Liver function changes: Regular blood tests are done to monitor liver health[1].
  • Biliary inflammation or necrosis: In rare cases, floxuridine can cause inflammation or damage to the bile ducts. This risk is reduced by adding dexamethasone to the infusion[3].
  • Pump-related complications: Issues with the pump or catheter may occur, requiring medical attention[2].

It’s important to discuss potential side effects and their management with your healthcare team before starting treatment with floxuridine.

Aspect Details
Primary Use Treatment of colorectal liver metastases
Administration Method Hepatic arterial infusion (HAI) via implanted pump
Common Combinations With systemic chemotherapy (e.g., oxaliplatin, irinotecan, capecitabine)
Patient Population Unresectable liver metastases, often after progression on first-line therapy
Key Outcomes Measured Tumor response, resection rates, progression-free interval, overall survival
Potential Advantages Higher local drug concentrations, potentially improved tumor response
Challenges Requires surgical pump placement, potential for hepatobiliary toxicity
Current Status Under investigation in multiple phase II and III clinical trials

FAQ

  • What is floxuridine and how is it used in these clinical trials? Floxuridine (FUDR) is a chemotherapy drug that is being studied for treating colorectal cancer that has spread to the liver. In these trials, it is typically administered via hepatic arterial infusion, which delivers the drug directly to the liver through a catheter and pump system.
  • What is hepatic arterial infusion (HAI) chemotherapy? Hepatic arterial infusion (HAI) chemotherapy is a method of delivering drugs directly to the liver through the hepatic artery. This allows for high concentrations of chemotherapy to reach liver tumors while minimizing systemic side effects.
  • What are the potential benefits of using floxuridine for colorectal liver metastases? Potential benefits include improved tumor response rates, increased rates of tumors becoming resectable (able to be surgically removed), and possibly improved survival compared to standard systemic chemotherapy alone for patients with liver metastases.
  • What are some of the side effects or risks of floxuridine treatment? Potential side effects include liver inflammation or damage, biliary complications, and pump-related issues. The trials are carefully monitoring patients for toxicity and adjusting doses as needed to find the optimal balance of efficacy and safety.
  • Who might be eligible for clinical trials using floxuridine? Eligibility varies by trial, but generally includes patients with colorectal cancer that has spread to the liver and is considered unresectable. Some trials focus on patients who have progressed after first-line chemotherapy or are receiving it as part of combination therapy.

Ongoing Clinical Trials on Floxuridine

  • Study on the Effectiveness of Floxuridine and Drug Combination for Patients with Unresectable Colorectal Liver Metastases

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness of Floxuridine with Gemcitabine and Oxaliplatin for Patients with Intra-hepatic Cholangiocarcinoma Not Suitable for Surgery

    Recruiting

    3 1 1 1
    Investigated drugs:
    Norway

  • Study on Treatment for Colorectal Liver Metastases Using Heparin, Dexamethasone, and Floxuridine for Patients with Heavy Tumor Burden

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on Chemotherapy with Irinotecan, Folinic Acid, Fluorouracil, Oxaliplatin, and Floxuridine for Patients with Colorectal Cancer Spread to the Liver

    Not recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Floxuridine (FUDR): A chemotherapy drug used to treat cancer, particularly liver metastases from colorectal cancer. It is often administered via hepatic arterial infusion.
  • Hepatic Arterial Infusion (HAI): A method of delivering chemotherapy directly to the liver through a catheter placed in the hepatic artery, allowing for high drug concentrations in the liver while minimizing systemic exposure.
  • Colorectal Liver Metastases: Cancer that has spread from the colon or rectum to the liver, a common site of metastasis for colorectal cancer.
  • Unresectable: Referring to tumors that cannot be completely removed by surgery, often due to their size, number, or location.
  • Progression-Free Interval (PFI): The length of time during and after treatment that a patient lives without worsening of their cancer.
  • Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Hepatic Pump: A small, implanted device used to deliver chemotherapy directly to the liver through the hepatic artery.
  • Systemic Chemotherapy: Chemotherapy that is given by mouth or injected into a vein and circulates throughout the entire body.
  • Resection: Surgical removal of part of an organ or structure. In the context of liver metastases, it refers to surgically removing the tumors from the liver.
  • Ablation: A minimally invasive procedure that destroys tumors without removing them, often using heat (radiofrequency ablation) or extreme cold (cryoablation).

References

  1. https://clinicaltrials.gov/study/NCT00587067
  2. https://clinicaltrials.gov/study/NCT01938729
  3. https://clinicaltrials.eu/trial/study-on-treatment-for-colorectal-liver-metastases-using-heparin-dexamethasone-and-floxuridine-for-patients-with-heavy-tumor-burden/
  4. https://clinicaltrials.gov/study/NCT00268463
  5. https://clinicaltrials.gov/study/NCT00002783
  6. https://clinicaltrials.gov/study/NCT03493061